

[Hydroxycarbamide \(hydroxyurea\)](#)

Essential medicine status

Section:

[10. Medicines affecting the blood](#) [10.3. Medicines for haemoglobinopathies](#)

ATC codes: [L01XX05](#)

EMLc

Indication

Other specified sickle cell disorders or other haemoglobinopathies ICD11 code: [3A51.Y](#)

INN

Hydroxycarbamide

Medicine type

Chemical agent

List type

Complementary

Formulations

Oral > Solid > dosage form: 200 mg ; 500 mg ; 1 g ; 100 mg (EMLc)

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Hydroxycarbamide \(hydroxyurea\)](#)

DrugBank

[Hydroxycarbamide \(Hydroxyurea\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of hydroxycarbamide 250 mg solid oral dosage from the EML and EMLc, and the addition of hydroxycarbamide 100 mg solid oral dosage form to the EMLc.